AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novartis Makes Takeover Bid for Avidity Biosciences with $4.3B Market Value
ByAinvest
Wednesday, Aug 6, 2025 8:36 pm ET1min read
Novartis has reportedly made a takeover offer for Avidity Biosciences, a biotech company with a market value of $4.3B. Avidity is developing medicines for muscular dystrophy and is working with advisers to assess its options. The deal could be a strategic move by Novartis to expand its biologics portfolio.
Swiss pharmaceutical giant Novartis has reportedly approached U.S. biotech company Avidity Biosciences for a potential takeover, according to reports from the Financial Times [1]. The deal, if successful, would be one of the largest acquisitions under Novartis' current CEO, Vas Narasimhan. Avidity Biosciences, with a market value of $4.3 billion, is developing treatments for rare muscle disorders, including muscular dystrophy.The news of the potential acquisition sent Avidity Biosciences' stock surging by more than 21% in midday trading, reaching $46.66 per share [2]. The company's market capitalization has approached $6 billion following the report [3]. Avidity Biosciences has three drugs in clinical testing, two of which could potentially be "multibillion-dollar drugs," according to its CEO, Sarah Boyce [4].
The acquisition would align with Novartis' strategic focus on expanding its biologics portfolio and strengthening its position in the rare disease treatment market [2]. Both companies have declined to comment on the matter [1, 3].
The discussions are at an early stage, and there is no guarantee that a deal will materialize [2]. Avidity Biosciences is reportedly working with advisers to assess its options [2]. The potential acquisition would be a significant move for Novartis, aiming to bolster its pipeline of medicines targeting rare genetic disorders.
References:
[1] https://www.investors.com/news/technology/avidity-biosciences-novartis-rumored-takeover-deal/
[2] https://www.investing.com/news/stock-market-news/avidity-biosciences-stock-soars-on-novartis-takeover-approach-report-4173978
[3] https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-weighs-deal-biotech-avidity-biosciences-ft-reports-2025-08-06/
[4] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TY1ON:0-novartis-weighs-deal-for-biotech-avidity-biosciences-ft-reports/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet